. 2020 Oct 16;11(9):2709–2718. doi: 10.1016/j.apsb.2020.10.013
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 2.
The designed PRMT inhibitors.